Lilly Drug Receives FDA Breakthrough Therapy Designation

(photo courtesy: Eli Lilly & Co.)

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

The U.S. Food and Drug Administration has granted a Breakthrough Therapy designation for donanemab, an antibody therapy for the treatment of Alzheimer’s disease from Indianapolis Eli Lilly and Co. (NYSE: LLY). The designation aims to expedite the development and review of drugs that are intended to treat a serious condition.

Lilly says the designation is based on clinical evidence for donanemab, which targets a modified form of beta amyloid called N3pG. The company’s Phase 2 trial, TRAILBLAZER-ALZ, studied the efficacy and safety of donanemab in patients with early, symptomatic AD.

Lilly intends to submit a biologics license application for donanemab under the accelerated approval pathway later this year.

You can learn more about the TRAILBLAZER-ALZ 2 study or to see if you prequalify by clicking here.